Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) and Merit Medical Systems (NASDAQ:MMSI – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations and earnings.
Valuation and Earnings
This table compares Vivos Therapeutics and Merit Medical Systems”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vivos Therapeutics | $17.44 million | 0.11 | -$21.17 million | ($1.90) | -0.05 |
| Merit Medical Systems | $1.61 billion | 3.22 | $128.49 million | $2.66 | 32.57 |
Merit Medical Systems has higher revenue and earnings than Vivos Therapeutics. Vivos Therapeutics is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Vivos Therapeutics has a beta of 6.37, meaning that its share price is 537% more volatile than the S&P 500. Comparatively, Merit Medical Systems has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of current recommendations and price targets for Vivos Therapeutics and Merit Medical Systems, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vivos Therapeutics | 1 | 1 | 2 | 0 | 2.25 |
| Merit Medical Systems | 0 | 5 | 8 | 0 | 2.62 |
Vivos Therapeutics currently has a consensus price target of $2.80, suggesting a potential upside of 2,757.14%. Merit Medical Systems has a consensus price target of $105.55, suggesting a potential upside of 21.83%. Given Vivos Therapeutics’ higher probable upside, research analysts clearly believe Vivos Therapeutics is more favorable than Merit Medical Systems.
Profitability
This table compares Vivos Therapeutics and Merit Medical Systems’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vivos Therapeutics | -122.00% | -2,325.64% | -102.01% |
| Merit Medical Systems | 9.94% | 14.12% | 8.37% |
Institutional and Insider Ownership
26.4% of Vivos Therapeutics shares are held by institutional investors. Comparatively, 99.7% of Merit Medical Systems shares are held by institutional investors. 1.4% of Vivos Therapeutics shares are held by insiders. Comparatively, 0.7% of Merit Medical Systems shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Merit Medical Systems beats Vivos Therapeutics on 11 of the 14 factors compared between the two stocks.
About Vivos Therapeutics
Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing oral appliances and related treatments for sleep-disordered breathing, including obstructive sleep apnea (OSA) and snoring. Its approach is designed to help improve upper-airway function through non-surgical, dentist-supervised therapies. The company’s primary products are its Vivos Complete Airway Repositioning and Expansion (CARE) oral appliances, which are customized for individual patients and intended for use during sleep.
About Merit Medical Systems
Merit Medical Systems develops, manufactures and markets medical devices used in diagnostic and interventional procedures. Its products support clinicians in areas including cardiology, radiology, oncology and endoscopy. The company’s portfolio includes devices and accessories for vascular access, diagnostic and therapeutic procedures, drainage, biopsy and embolization. Merit serves hospitals, clinics and other healthcare providers through direct sales and distribution channels. Founded in 1987 and headquartered in South Jordan, Utah, Merit Medical serves customers in the United States and internationally.
Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
